Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carto...

FDA Recall #D-0242-2026 — Class II — December 12, 2025

Recall #D-0242-2026 Date: December 12, 2025 Classification: Class II Status: Ongoing

Product Description

Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway, NJ 07056 USA, Manufactured by: N.V. Organon, 5349 AB Oss, The Netherlands, a subsidiary of Organon & Co., Jersey City, NJ 07302, USA NDC 0085-2224-02.

Reason for Recall

Presence of particulate matter: potential presence of metal particulates in the product.

Recalling Firm

Merck Sharp & Dohme LLC — Wilson, NC

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

845 kits

Distribution

Nationwide in the USA

Code Information

Lot#: Z012339, Z010344, Z009908, Z009909, Exp Date 12-31-2026

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated